| Literature DB >> 33930627 |
Huachun Liu1, Simone Rauch1, Bryan C Dickinson2.
Abstract
RNA has long been an enticing therapeutic target, but is now garnering increased attention, largely driven by clinical successes of RNA interference-based drugs. While gene knockdown by well-established RNA interference- and other oligonucleotide-based strategies continues to advance in the clinic, the repertoire of targetable effectors capable of altering gene expression at the RNA level is also rapidly expanding. In this review, we focus on several recently developed bifunctional molecular technologies that both interact with and act upon a target RNA. These new approaches for programmable RNA knockdown, editing, splicing, translation, and chemical modifications stand to provide impactful new modalities for therapeutic development in the coming decades.Entities:
Keywords: CIRTS; CRISPR/Cas13; Epitranscriptomics; Genetic therapies; Transcriptome regulation
Mesh:
Substances:
Year: 2021 PMID: 33930627 PMCID: PMC8548394 DOI: 10.1016/j.cbpa.2021.03.004
Source DB: PubMed Journal: Curr Opin Chem Biol ISSN: 1367-5931 Impact factor: 8.972